Breaking News Headlines Today | Ground News

See every side of every news story

MyChesCo image

News from MyChesCo

MyChesCo’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

MyChesCo’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about MyChesCo

Where is MyChesCo located?MyChesCo's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top MyChesCo News

Democrats Call for Noem's Removal After Second Fatal Shooting by DHS Agent

Democrats Call for Noem's Removal After Second Fatal Shooting by DHS Agent

43% Right coverage: 21 sources

(The Center Square) – In wake of the second fatal shooting in Minneapolis over the weekend, Democrats are overwhelmingly demanding the removal of Department of Homeland Security Secretary Kristi Noem.See the Story

Apple, Google host dozens of AI ‘nudify’ apps like Grok, report finds — REUTERS / Dado Ruvic

Google · United States

Apple, Google host dozens of AI ‘nudify’ apps like Grok, report finds

45% Center coverage: 9 sources

The Apple and Google app stores have applications that generate images of women with their clothes removed with AI, a tech watchdog reported Tuesday.See the Story

Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight - Roche Holding (OTC:RHHBY)

Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight - Roche Holding (OTC:RHHBY)

67% Center coverage: 6 sources

Roche Holdings AG (OTC:RHHBY) on Tuesday released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity. CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities. Trial Data The 469-patient trial was designed to evaluate the efficacy and safety of CT-388 at low, middle, and high doses. I…See the Story

Breaking News Topics Related to MyChesCo